April 27, 2018
Ono Pharmaceutical said on April 26 that it has submitted a new drug application for the pheochromocytoma (PCC) treatment metyrosine, a tyrosine hydroxylase inhibitor licensed from Valeant Pharmaceuticals International. The drug, coded ONO-5371, was filed for the improvement of excessive...read more